Platelet-rich plasma in the management of Asherman syndrome: case report

Aghajanova, Lusine; Cedars, Marcelle I.; Huddleston, Heather G.

doi:10.1007/s10815-018-1135-3

Cited by 38 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…reporting prospective cohort studies with using patients' prior cycles as control (42,46,47) Successful pregnancies have been described in the setting of treated AS or thin lining after PRP infusion even without increased endometrial thickness, suggesting that PRP might not only improve proliferation of endometrial cells, but could probably modulate endometrial functionality and receptivity on molecular level (45,47).…”

Section: Tablementioning

confidence: 99%

Should we consider alternative therapies to operative hysteroscopy for the treatment of Asherman syndrome?

Santamaría

Liu

Aghajanova

et al. 2020

Fertility and Sterility

View full text Add to dashboard Cite

show abstract

Section: Tablementioning

confidence: 99%

Should we consider alternative therapies to operative hysteroscopy for the treatment of Asherman syndrome?

Santamaría

Liu

Aghajanova

et al. 2020

Fertility and Sterility

View full text Add to dashboard Cite

show abstract

“…There are only a few case reports of different treatment options for refractory AS. Aghajanova et al [30] have reported two cases in which the uterine cavity was infused with autologous, platelet-rich plasma after hysteroscopy to improve endometrial growth and function. Platelets in the plasma have been shown to contain alpha-granules, which store cytokines and growth factors involved in cell migration, proliferation, angiogenesis and differentiation, and are released at the site of injury.…”

Section: Current Treatment Optionsmentioning

confidence: 99%

Cell and biomaterial-based approaches to uterus regeneration

Liu

Wang

et al. 2019

Regenerative Biomaterials

View full text Add to dashboard Cite

Asherman’s syndrome (AS) is an endometrial disorder in which intrauterine adhesions crowd the uterine cavity and wall. The fibrotic adhesions are primarily the result of invasive uterine procedures that usually involve the insertion of surgical equipment into the uterus. This syndrome is accompanied by a number of clinical manifestations, including irregular or painful menstruation and infertility. The most prevalent treatment is hysteroscopy, which involves the physical removal of the fibrous strands. Within the last decade, however, the field has been exploring the use of cell-based therapeutics, in conjunction with biomaterials, to treat AS. This review is a recapitulation of the literature focused on cellular therapies for treating AS.

show abstract

“…Complications of hysteroscopic surgery include bleeding, uterine perforation, and pelvic infection. However, in some patients, infertility is not treated even after the treatment of Asherman's syndrome (intrauterine adhesions) (4,5). The main goal of treatment in this syndrome is to repair the damaged endometrium as well as create a physiological condition suitable for pregnancy.…”

Section: Introductionmentioning

confidence: 99%

Role of hyaluronic acid intrauterine injection in the prevention of Asherman’s syndrome in women undergoing uterine septum resection: An RCT

Tafti

Javaheri

Firoozabadi

et al. 2021

IJRM

View full text Add to dashboard Cite

Background: Adhesion due to intrauterine surgery such as septal resection associated with damaged endometrium can increase the risk of Asherman’s syndrome. The main goal of treatment in this syndrome is to repair the damaged endometrium for creating a physiological pregnancy. Objective: To investigate the effect of intrauterine injection of hyaluronic acid on the prevention of Asherman’s syndrome in women undergoing uterine septum resection. Materials and Methods: In this double-blind randomized clinical trial, 65 women undergoing the uterine septum resection were divided into two groups; the case group (n = 34) and the control group (n = 31). Immediately after the septal resection with a resectoscope, 1cc of hyaluronic acid gel in the case group and 1cc normal saline solution as a placebo in the control group was injected into the uterine cavity. After two months, existence of intrauterine adhesions in the both groups was examined by the hysteroscope and assessment of menstrual patterns, according to the American Society for Reproductive Medicine criteria. Results: Our results showed that after intervention, the incidence of Asherman’s syndrome in the control group was higher than the case group (p = 0.012). In the case group, only four women had poor adhesion (Asherman’s syndrome) at the end of the study, while the rest of them were free of any adhesions in the uterine cavity. In the control group, however, only 19 were free of intrauterine adhesions and 12 had mild symptoms. Conclusion: The results of the study exhibited the hyaluronic acid capacity to reduce the risk of Asherman’s syndrome in women with endometrial damage following a septal resection surgery. Key words: Asherman’s syndrome, Septum, Uterine, Hyaluronic acid, Resection.

show abstract

Platelet-rich plasma in the management of Asherman syndrome: case report

Cited by 38 publications

References 36 publications

Should we consider alternative therapies to operative hysteroscopy for the treatment of Asherman syndrome?

Should we consider alternative therapies to operative hysteroscopy for the treatment of Asherman syndrome?

Cell and biomaterial-based approaches to uterus regeneration

Role of hyaluronic acid intrauterine injection in the prevention of Asherman’s syndrome in women undergoing uterine septum resection: An RCT

Contact Info

Product

Resources

About